Derivative exercise or conversion — not an open-market buy.
Traded Jun 29, 2026 · Filed Jul 1, 2026
Roivant Sciences's Reporting person sold $6.89M of Roivant Sciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$6,888,000
Shares × reported transaction price
40 days after results of May 20, 2026, 38 days before results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.0% | −0.1% | +3.1% |
| 30 days | −3.2% | +0.2% | −3.4% |
| 90 days | +4.2% | +2.5% | +1.7% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$6.99M of Roivant Sciences
Automatic saleDerivative exercise or conversion — not an open-market buy.